Stocks Slide for Third Straight Day

Remember, we need your input to make next week's new Zacks Ultimate Strategy Session episode the best it can be. There are two ways you can participate:

1) Zacks Mailbag: In this regular segment, Kevin Matras will answer your questions ranging from current market conditions, general investing wisdom, usage of the Zacks Rank or any resources of and more. Pretty much anything goes.

2) Portfolio Makeover: Jeremy Mullin and Neena Mishra, CFA, FRM, will review a customer portfolio to give feedback for improvement. No need to send us personal information such as dollar value of holdings. Simply email us with all of the tickers you own.

Just make sure to email your submissions for either one, or both, by Thursday morning, March 7. Email now to

Well, we're really stuck. The major indices have closed lower for three consecutive days as the market just can't seem to find any reason to move higher.

The NASDAQ had been outperforming its counterparts earlier in the week, but today it led the way lower with a slide of 0.93% (or about 70 points) to 7505.92.

The S&P was above 2800 as recently as last Friday. Since then though, the index has been retreating from that mark. It was down 0.65% in the session to 2771,45.

The Dow slipped another 0.52% (or around 133 points) to 25,673.46.

Fortunately, we're not having a severe selloff at the moment… even though it sometimes feels that way. Stocks are only down by approximately 1% during this losing skid, which means they're still up double digits year to date.

The first two months of 2019 were so easy, as the market was feeling good on trade deal optimism and the "patient" Fed. But its not so simple anymore.

Investors are getting concerned about slowing growth, while a trade deal remains up in the air despite a number of positive headlines over the past few weeks. But the biggest worry right now is that a trade agreement has already been priced into the market, which means that an official deal may not have much of an impact.

But there's still enough time this week to keep the market moving higher. Remember, the NASDAQ is on a 10-week winning streak while the S&P and Dow have each advanced in 9 of the past 10 weeks.

We need a catalyst! The meeting between President Trump and China President Xi won't happen until the end of this month at the earliest, but another piece of encouraging trade news would always be welcome. Plus, everyone is watching for the big jobs report on Friday.

Today's Portfolio Highlights:

Counterstrike: With the market sputtering and more downside possible, Jeremy decided this was a good time to short a couple of names. Inc. (WUBA) missed earnings by 20% last week, sending shares of this Chinese online marketplace lower by about 15%. Meanwhile, Inc. (STMP) had a "disastrous" earnings report after this Internet-based postage company lost its deal with USPS. The editor believes both of these names have further to fall, so he shorted each with a 5% allocation. Read the full write-up for more on these moves and to look at their charts.

Insider Trader: The portfolio added Diebold (DBD) and Zimmer Biomet (ZBH) on Wednesday with 10% allocations for each. These companies are both up so far in 2019, but that didn't keep insiders from buying shares in recent days. Tracey thinks this could be a signal that these stocks have further to climb. DBD provides connected commerce solutions to financial institutions, while ZBH is a large-cap medical device maker. Read the full write-up for specifics on these new buys. By the way, the editor also sold the rest of Live Oaks (LOB) for a more than 9% return in a little over a month.

Home Run Investor: The market is slowing down a bit as we are still waiting for a trade deal. Brian Bolan doesn't know how long this malaise will last, so he wants more diversification in the portfolio to prepare for any outcome. On Wednesday, the editor added Resources Connection (RECN), which is a management consulting firm with several thousand clients. Therefore, it has a pretty reliable and visible revenue stream. The stock has a good valuation and earnings estimates that have improved over the past 90 days. Read the complete commentary for more on this new pick and be ready for another buy tomorrow.

Healthcare Innovators: The JPM Healthcare Conference in early January was a nice turning point for Neurocrine Biosciences (NBIX), as shares bounced off support at $68 and are now at around $74. Kevin thinks the risk/reward is very favorable at the moment for such an innovative nervous systems company, which has a lucrative partnership with AbbVie that bodes well for the future. Read the complete commentary for specifics on this new addition.

All the Best,

Jim Giaquinto Recommendations from Zacks' Private Portfolios:

Believe it or not, this article is not available on the website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >>

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More